Pelacarsen (TQJ230)

DRUG3 trials

Sponsors

University Medical Centre Ljubljana, Novartis Pharmaceuticals

Conditions

Acute Coronary SyndromeAtherosclerotic Cardiovascular DiseaseCardiovascular Disease and Lipoprotein(a)Genetic PolymorphismsInflammationLipoproteinemia

Phase 3

Pelacarsen Roll-over Extension Program

RecruitingNCT06875973

Novartis PharmaceuticalsAtherosclerotic Cardiovascular Disease

Start: 2025-05-19End: 2030-12-08Target: 599Updated: 2026-07-29

An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)

RecruitingNCT07517263

Novartis PharmaceuticalsCardiovascular Disease and Lipoprotein(a)

Start: 2026-05-11End: 2030-01-09Target: 5700Updated: 2026-09-04

Unknown Phase

Influence of Pelacarsen on Patients After Myocardial Infarction With High Lp(a) Values (PEMILA)

WithdrawnNCT04993664

University Medical Centre LjubljanaAcute Coronary Syndrome, Genetic Polymorphisms, Inflammation +1

Start: 2021-10-01End: 2022-10-01Updated: 2022-01-03